🔎 Trials Near Me

Utama › Tumor Wilms › Tennessee

Kajian klinikal Tumor Wilms di Tennessee

6 kajian untuk Tumor Wilms sedang mencari peserta di lokasi di Tennessee.

Bandar di Tennessee

Teks kajian rasmi (Bahasa Inggeris)

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

  • Saint Jude Children's Research Hospital, Memphis
Mengambil pesertaFasa 2
Umur 12 hingga 39 · Semua jantina · Dikemas kini 29 Sep 2026 · NCT04616560

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  • East Tennessee Childrens Hospital, Knoxville
  • Saint Jude Children's Research Hospital, Memphis
  • The Children's Hospital at TriStar Centennial, Nashville
  • dan 1 lagi
Mengambil pesertaFasa 2
Sehingga umur 30 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04322318

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Saint Jude Children's Research Hospital, Memphis
Mengambil pesertaFasa 1/2
12 Months – 30 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04851119

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

  • St. Jude Children's Research Hospital, Memphis
Mengambil pesertaFasa 1
Sehingga umur 21 · Semua jantina · Dikemas kini 19 Mei 2026 · NCT04897321

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

  • St. Jude Children's Research Hospital, Memphis
Mengambil pesertaFasa 1/2
12 Months – 30 Years · Semua jantina · Dikemas kini 19 Mei 2026 · NCT04901702

Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation

  • St.Jude Children's Research Hospital, Memphis
Mengambil pesertaFasa 2
Semua umur · Semua jantina · Dikemas kini 23 Apr 2026 · NCT04968990

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.